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Blood coagulation, an example of heterogeneous biokatalysis
H. C, HEMKER
( Department of Biochemistry, Biomedical Centre,
State University of Limburg, Maastricht)
The central process in the sequence of blood coagulation is the
enzymatic cleavage of prothrombin (factor II) into its activation
peptide and thrombin (factor IIa). This reaction involves the
splitting of two peptide bonds in the single chain prothrombin
molecule. It is catalysed by a serine protease called factor Xa.
Factor Xa is able to split prothrombin when both molecules meet
in free solution. As soon as phospholipids and an accessory pro-
tein, called factor V, are present, the rate of the reaction can
increase up to 100 000 fold.
It is one of the main aims in our laboratory to understand the
mechanism of this reaction. Not only because it is of intrinsic bio-
chemical interest but also because of its enormous rnedical impor-
tance. It has become clear that thrombin generation is a crucial
step in the genesis as well as in the fatallate complications of athero-
sclerosis. Now this condition accounts for well over half of all deaths
in western society so it can hardly be denied medical importance.
Without exploring the link between thrombin generation and
atherosclerosis in any detail, it can be indicated that there is good
argument in favour of the view that the generation of platelet
thrombi is essential in the development of atherosclerosis and that
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thrombin plays the key role in the generation of irreversible thrombi.
At the other end of this process occluding thrombosis on a (rup-
tured) atherosclerotic plaque often announces the final stage of
atherosclerotic disease. Understanding of the mechanism of throm-
bin formation therefore is of both medical and scientific interest.
We approached the problem mainly by kinetic means, i.e. by
analysing the relation between the activity of the prothrombin
converting eflzyme, its composition and the concentration of its
substrate prothrombin. This prothrombinare complex in its complete
form consists of the active site bearing serine protease called acti-
vated factor X (f Xu); an accessory protein factor (para-enzyme)
called factor Vu (fVu); phospholipid (PL) and calcium ions.
Incomplete forms in which the active site bearing protease is pre-
sent do show activity, however.
First, I will introduce the different components of the system
under study and then discuss their interaction.
Prothrombin is a minor protein in plasma : about 2 ptvt (-
150 mgilitre). It is a single chain protein of 72 000 daltons contain-
ing 582 amino-acid residues. It is synthesizedby the liver in a two-
step procedure. The first step is normal ribosomal protein synthesis.
The second one is a vitamin K-dependent carboxylation of 10
glutamic acid residues in the N-terminal end of the molecule.
VnnNrsER et al. (1978) in our laboratory recently purifled the car-
boxylase responsible for this reaction. It is an interesting process,
in many respects more akin to oxidative phosphorylation than to
known mammalian carboxylations.
It needs Oz, CO2, an electron donor like NADH as well as redu-
ced vitamin K, but ATP or biotin are not involved in the reaction.
Vitamin K deficiency inhibits the second step of prothrombin
synthesis and causes the uncarboxylated precursor to appear in
the blood stream.
In fact, it was by this phenomenon that we discovered the two-
step synthesis (Hnrr,trnn et al., 1963). y-Carboxyglutamic acids are
present in blood clotting factors II, VII, IX and X that are all
known to be vitamin K-dependent, as well as in a flfth plasma
protein, called protein C. This protein acts as an anticoagulant by
breaking down factor V (SrnNrro , I976). The role of the y-carboxy-
glutamic acid residues lies in binding the proteins vra Ca2+ ions
to the negatively charged surface of phospholipid bilayers. Two
cuts have to be made into the prothrombin molecule in order to
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produce thrombin; the first one after residue 274 yields the N-
terminal activation peptide (called fragment l-2) and an inter-
mediate without enzymatic activity, called prethrombin2;the second
one is in prethrombin 2 after residue 318 and yields the A and B
chains of thrombin, linked together by a disulfide bridge.
Factor X is a proenzyme like prothrombin. It shows marked
homologies with prothrombin both in its heavy chain, that bears
the active site and in the N-terminal part of the light chain that
contains 12 gla residues. In order to be activated a small activation
peptide has to be split off from the C-terminal patt of the heavy
chain. The activation of factor X can be caused by either factor IXa
or factor VIIa, both of which act in complexes with phospholipids
and accessory proteins, very much like factor X" does in activating
prothrombin.
The phospholipids active in blood coagulation can be any mixture
of negatively charged phospholipids presented at the outer surface
of a bilayer, in a vesicle, liposome or cell membrane. In coagulating
blood they will mostly be the phospholipids that normally form
the inside of the platelet-plasma membrane. Zwttr et al' (1980)
in our laboratory have shown recently that a flip-flop of the pla-
telet membrane, i.e. the presentation of a paft of the interior face
of the membrane to the outside is an essential patt of the physio-
logical thrombin forming process. In most of the kinetic experi-
ments we used synthetic phospholipids usually equal amounts of
di [14C] phosphatidylserine and -choline.
Factor V is a trace protein in plasma (0.02 mg/ml) with a mole-
cular weight of 240 000. It has no recognized enzymatic activity of
its own. It is a one-chain molecule that is cleft by thrombin into
the active form that accelerates factor X' activity.
Early kinetic experimefis (Hnurnn et al., 1967) had shown that
the three constituents of the prothrombinase complex influence
the prothrombinase activity in principle in the same way. When
the concentration of two is kept constant increase of the concen-
tration of the third increases the activity to a fixed upper limit
that is approached by a saturation curve. Apart from this, phospho-
lipid in high concentrations appeared to diminish the activity.
This led to a model in which factors Xa and V", adsorbed in juxta-
position on the phospholipid surface, form the active enzyme.
The saturation observed is the saturation of the sites binding
factor X" (or factor Vr) at the phospholipid. Increasing the amount
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of phospholipid increases the number of binding sites. This situa-
tion will first draw protein molecules from the solution and in-
crease the number of active enzyme complexes. Later the surface
offered becomes so large that it becomes difficult for factor Xa
and factor Va molecules to find each other and achieve juxtaposi-
tion. This explains the inhibition at high phospholipid concentra-
tions. Recently, it became possible to obtain both factor X* and
factor V' in a pure state; also pure prothrombin could be prepared
in substrate quantities. This, together with the advent of a chro-
mogenic substrate for thrombin, which made it possible to deter-
mine thrombin generated with great precision by spectrophoto-
metry, enabled us to carry out kinetic experiments with much more
precision and to extend them substantially. Drs. RosINc, TlNs and
vAN DIEIJEN were able to determine K- and k.u, of prothrombinase
for prothrombin for various compositions of the enzyme complex.
Their first finding was that the presence of phospholipids decreases
Km of prothrombin activation by a factor of about 1 000 but has
hardly any effect on k,ur. Factor V" on the other hand, increases
k"ot by a factor of about 1 000 but does not influence K-. This
points to essentially different functions for both accelerators,
and automatically prompted a search for a mechanistic explanation
of these phenomena (RosINc et al., 1980).
The first hint for the role of phospholipids was that the K'n deter-
mined in the experiments appeared to be a function of the phospho-
lipid concentration. With the aid of the binding constant of pro-
thrombin for the well defined phospholipid mixture we used and
the number of binding sites reported in the literature (NnrsnsrurN
& Bnoosnlvs, 1977) we could calculate the number of phospho-
lipid-bound substrate molecules at the apparent Km found at a
given phospholtpid concentration. It then appeared that half
maximal reaction velocity occurred at a fixed concentration of
phospholipid-bound substrate molecules, independent of the
amount of phospholipid present (apart from the dilution effect
discussed above). So apparently only the concentration ofphospho-
lipid-bound substrate is of consequence for the enzyme, i.e. the
reactions take place between molecules "skating" on the surface.
"Skating" introduces the concept of lateral mobility which is essen-
tial in this model. Molecules immobilized on the surface would have
no possibility to interact. It is known that molecules adsorbed
onto, or in phospholipid bilayers do have such mobility. Calcula-
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tion of the collision frequency between adsorbed molecules indi-
cates that, although the lateral diffusion constant is less than that
in free solution, still the number of collisions per unit time can be
100 to 1 000 times higher due to the concentration at the surface.
The explanation of the effect of factor Vu on Z is less straight-
forward than that of phospholipid.
In the first place, we have to recognize that k"u, of serine proteases
with small substrate is of the order of 10 to 100 per second. Factor
Xu alone turns over prothrombin at the rate of about one per
minute. When factor V is present this brings about a I 000 fold
increase of the turnover. So factor V enables the active centre of
factor X, to attain its normal achievement rather than causing an
acceleration per se. A second interesting observation was made
when a tetrapeptide and prothrombin were offered as competing
substrates to factor X" (in the presence or the absence of phospho-
lipid). When both are present at a concentration equal to their K-,
one would expect 50 /, inhibition of the conversion of each of them.
It turned out that the tetrapeptide does inhibit the prothrombin
conversion but unexpectedly prothrombin does not inhibit the
splitting of the peptide, even at concentrations markedly above Km.
This can only mean that there are unproductive prothrombin-en-
zyme complexes (or product-enzyme complexes) that have their
active centres free to handle the small substrate. It is tempting to
conjecture that factor V serves to turn unproductive complexes
into productive ones, that is to direct the active centre of the
enzyme to the vulnerable sites in the substrate or, alternatively,
to ensure a rapid dissociation ofthe products.
Kinetic experiments were also carried out with the factor-X-
activating complex, that consists of a cornplex of factor lX, bearing
the active site and factor VIIIa (thrombin turns factor VIII lnto its
active form) again at the surface of a phospholipid bilayer. It
became clear that this complex is in every respect comparable to
prothrombinase (VnN DmrrnN et al., 1979). There is another fac-
tor X-activating complex that consists of factor VII,, phospholipid
and an intracellular protein. This enzyme has been studied in Ne-
mersons laboratory and again - as far as can be judged at this mo-
ment - the same picture emerges (Snvrnnrnc et al., 1977).
Recent research (Osrrnuo & R.q.p.{ponr, 1977; GRrrrrN, personal
communication) has revived the interest in a phenomenon already
signaled by Josso & Pnou-WARTELLE in 1965 pertaining to the
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beginning of the coagulation process. It is customary to distinguish
in coagulation the so-called extrinsic and intrinsic pathway of
thrombin formation. The extrinsic pathway is started by wounded
tissue. By the mechanisrn outlined in the paragraph above with
factor VII1 this causes a factor X-activating enzyme complex to
arise.
The intrinsic pathway is triggered by the adsorption of high
molecular weight kininogen and factor XII onto a wettable sur-
face. Via a mechanism that we will not discuss in detail, and in
which factor XI and prekallikrein partake, this leads to the gene-
ration of active factor XI that can activate factor IX'
Intrinsic and extrinsic pathway are convenient in describing the
situation in a test tube where either no, or an excess of tissue
thromboplastin is added. It became clear that when small amounts
of tissue thromboplastin are present factor VII is activated to a
small extent and in its turn activates both factor IX and factor X.
The active factor IX (together with factor VIII) and phospholipid
substantially helps in activating factor X. The kinetic mechantsm
behind this phenomenon probably lies in the accelerating effect
of the insertion of an extra step in the enzyme cascade. When fac-
tor VIIa itself converts l0 molecules of factor X per second and
only one molecule of factor IX, then in the first second the direct
action is more important than the indirect one. When factor IXu
is as good an activator of X as factor VII. is, this advantage would
be over after one second. After two seconds the direct and indirect
pathway would be of equal importance, and later the indirect way
yia factor IXu would gradually gain over the direct one. Kinetic
experiments and precise mathematical modelling will eventually
have to substantiate this gross numerical reasoning' Anyhow,
it is clear from the experiments of GnrrrIN (personal communica-
tion) that, under circumstances where no contact activation takes
place and small amounts of tissue thromboplastin are present, the
activation of factor X is substantially retarded in plasmas deficient
in factor IX or VIII but not in plasmas deficient in the contact
factors (f XII, f XI). Now, small amounts of tissue thromboplastin
and absence of contact activation very probably are much more
like the situation in a wound in vivo, than are either excess of tissue
thromboplastin or its complete absence. So a pathway viafactorYII,
and factors VIII and IX is a plausible candidate for physiological
thrombin generation.
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This gives a lead to the solution of one of the standing paradoxes
in blood coagulation research : why is it that Mr. Hageman, the
patient with factor-Xll-deficiency, never bled, and died of throm-
bosis whereas haemophiliacs (patients with factor VIII-o r factor
IX-deficiency) have major haemostasis problems ? It is the charm
and the curse of blood coagulation research that it switches back
and forth between "pure" biochemistry, physiology and pathology.
Those who are interested in it hope that the interdisciplinary
character of their field of interest in the barren times ahead for
biochemical research will aid keeping the subject alive, but they
fear at the same time, both for themselves and for the patients,
that an interdisciplinary field may be more vulnerable than esta-
blished disciplines so that they may be left sitting between two
chairs.
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